Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of conventional vs dose-intensive adjuvant temozolomide in newly diagnosed glioblastoma
2005-005177-29Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Overall survival and Progression-free survival. Started Jun 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2005-005177-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005177-29.